Neuronal Cell-Free DNA Methylation for Pre-Symptomatic Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neurodegenerative conditions such as Alzheimer's and Parkinson's disease rely on symptom-based tests, which are ineffective for early detection, leading to irreversible neuronal cell death without preventive treatment.
Innovation Solution
A blood-based diagnostic tool that amplifies and sequences cell-free DNA to analyze neuronal methylation patterns, using a python-derived pipeline to identify pre-symptomatic neurodegenerative conditions by comparing neuronal DNA percentages to controls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If symptom-based tests are used for diagnosis, then current diagnostic standards can be maintained, but early detection capability is lost
Solution Approach 1:
The patent extracts and analyzes specific methylation signatures from cell-free DNA that are indicative of neurodegenerative conditions, separating the diagnostic signal from the complex background of genomic data. This allows early detection by focusing on specific epigenetic markers rather than requiring full symptom manifestation.
Solution Approach 2:
The patent replaces mechanical/physical symptom-based assessment with molecular-level epigenetic analysis. By substituting clinical observation with DNA methylation pattern detection, the system achieves earlier and more objective diagnosis before neurological symptoms become apparent.
2Loss of time
If symptom-based diagnosis is used, then existing clinical protocols can be followed, but treatment timing is delayed until irreversible damage occurs
Solution Approach 1:
The patent performs preliminary detection of neurodegenerative conditions by analyzing methylation signatures before symptoms manifest. This advance detection enables treatment to be initiated in the pre-symptomatic stage, preventing or delaying irreversible neuronal damage while maintaining high diagnostic accuracy through epigenetic marker analysis.
3Measurement precision
If methylation signature analysis is implemented, then pre-symptomatic detection is enabled, but diagnostic procedure complexity increases
Solution Approach 1:
The patent segments the complex diagnostic process into distinct components: (1) cell-free DNA extraction from blood samples, (2) targeted amplification of specific genomic regions, (3) methylation signature analysis using bisulfite conversion and sequencing, and (4) computational interpretation of results. This segmentation manages complexity by breaking down the overall diagnostic workflow into standardized, manageable steps.
Solution Approach 2:
The patent uses bisulfite conversion as an intermediary chemical process that transforms unmethylated cytosine residues into uracil while leaving methylated cytosine unchanged. This intermediary step creates a detectable chemical difference that enables subsequent sequencing and analysis to distinguish methylated from unmethylated regions, facilitating pre-symptomatic detection without requiring direct observation of neuronal damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection of neurodegenerative diseases before symptom onset, allowing for timely therapeutic intervention to prevent or delay disease progression.
Implementation Method 1
analyzing a methylation pattern of the cell-free DNA
Data Source
AI summary
Disclosed herein is a blood based two-part diagnostic tool designed to diagnose pre-symptomatic neurodegenerative disease. Part one consists of an assay designed to amplify and sequence pre-specified regions of cell free DNA. Part two consists of a python-derived pipeline that analyzes methylation signatures to identify neuronal-derived DNA and provide a diagnosis of pre-symptomatic neurodegenerative disease.